Fig. 11
From: Celastrol slows the progression of early diabetic nephropathy in rats via the PI3K/AKT pathway
The effects of Celastrol on LC3II (B) protein in the DN rat model based on a WB assay. (A) Western blot images of LC3II. DN group, high-fat and high-glucose diet-fed STZ-induced DN rats. DN + CL group, DN rats were given by gavage low dose (0.5 mg/kg) Celastrol. DN + CH group, DN rats were given by gavage high dose (1.5 mg/kg/d) Celastrol. DN + INH group, DN rats were intraperitoneally injected with LY294002 (1.2 mg/kg/d). Following the once per day administration of Celastrol or LY294002 for 4 weeks for the intervention, rats were sacrificed and the LC3II protein levels determined by a WB assay of renal tissues. The results were quantified by normalizing to β-actin. * p < 0.05, ** p < 0.01 compared to NC, # p < 0.05, ## p < 0.01 compared to DN. DN, diabetic nephropathy. We used the one-way analysis of variance (ANOVA), followed by Turkey’s multiple comparison test to analyze the differences